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The effect of EGF stimulation and its inhibition with gefitinib (‘Iressa’, ZD1839), an epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor, has been investigated in two EGFR-positive human bladder tumour cell lines, RT112 and RT4. The growth of RT112
cells in a medium containing 10% foetal bovine serum was inhibited by 50% with 10mM gefitinib, whereas this dose completely
inhibited RT4 cell growth. Cells were more sensitive to growth inhibition in the serum-free medium. Increased growth of cells in the
serum-free medium was observed with 10 or 50ngml
1 EGF and the proliferative effect of EGF stimulation in both cell lines was
inhibited in the presence of 1mM, but not 0.1mM gefitinib. Zymography of the conditioned medium from RT112 cells treated with
EGF and gefitinib showed a decrease in matrix metalloproteinase 2 (MMP2) concentrations. Western blot analysis showed that tissue
inhibitor of metalloproteinase 1(TIMP1) increased in the conditioned medium from RT112 cells treated with EGF, and this was
partially inhibited with both 1 and 5mM gefitinib. Conversely, TIMP2 decreased with EGF stimulation and this was reversed with
gefitinib. Tissue inhibitor of metalloproteinase 1 had no effect on the growth of either cell line. These studies show alterations in the
balance of MMPs and their inhibitors in EGF-stimulated bladder tumour cells, which are reversed by gefitinib, suggesting gefitinib
should be investigated for its effect on human bladder tumours.
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Growth factors and their receptors are important in tumour
development and progression. Several studies have demonstrated
that the presence of epidermal growth factor receptor (EGFR) in
bladder cancer is associated with high tumour stage and grade, and
is a strong independent predictor of tumour progression and poor
long-term survival (Lipponen and Eskelinen, 1994; Mellon et al,
1995). Bladder cancer is the fifth most common cancer in men, and
transitional cell carcinoma of the bladder can be broadly divided
into superficial (Ta and T1) or muscle invasive (T2, T3 and T4)
forms. Approximately 50–70% of superficial tumours recur and
10–20% of these will become invasive. At present there is no
reliable method to predict which superficial tumours will show
invasive progression or metastasise.
Epidermal growth factor receptor is a member of the erbB family
of cell surface receptors, which comprises four homologous
receptors: EGFR (erbB-1/HER1); erbB-2 (HER2/neu); erbB-3
(HER3) and erbB-4 (HER4). These receptors are composed of an
extracellular ligand-binding domain, a transmembrane domain and
an intracellular protein kinase domain. Ligand-binding activates
the EGFR by inducing homo- or hetero-dimerisation with other
members of the erbB family, resulting in autophosphorylation of
both intracellular tyrosine kinase domains. This initiates a cascade
of intracellular signalling events (Olayioye et al, 2000).
Epidermal growth factor receptor signalling is critical not only
for cell proliferation but also in other processes crucial to cancer
progression, and EGFR is therefore a target for anticancer
therapies. One approach for the therapeutic blockade of EGFR
signalling has been the discovery and development of low
molecular weight compounds that inhibit the activation of the
EGFR tyrosine kinase. Gefitinib (‘Iressa’, ZD1839) is an orally
active EGFR tyrosine kinase inhibitor (EGFR-TKI). It is a low
molecular weight, synthetic quinazoline derivative that blocks
signal transduction pathways implicated in the proliferation and
survival of cancer cells (Wakeling et al, 1996). Gefitinib is currently
undergoing clinical cancer trials, both as a single agent or in
combination with established cytotoxic agents (Ciardiello and
Tortora, 2001). This, and other EGFR-TKIs, has recently been
reviewed (Wakeling, 2002).
The matrix metalloproteinases (MMPs) are a family of
proteolytic enzymes present in both normal and pathological
tissues in which matrix remodelling is involved, including
embryonic development, wound healing, arthritis, angiogenesis
and tumour invasion and metastasis. The MMPs, which are
secreted or membrane bound, contain a zinc atom at their active
site. The expression of MMPs is primarily regulated at the level of
transcription, and MMPs are synthesised as latent proenzymes
requiring extracellular proteolytic activation. Activity is also
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sregulated by endogenous tissue inhibitors of metalloproteinases
(TIMPs), which bind to activated MMPs in a 1:1 molar
stoichiometry. In some cell lines, TIMPs are reported to have a
stimulatory effect on cell growth. Both the MMPs and TIMPs have
been the subject of several recent reviews (Cox and O’Byrne, 2001;
Egeblad and Werb, 2002; Vihinen and Kahari, 2002).
In bladder cancer patients, urinary MMP1 concentration has
been reported to increase significantly with increased stage and
grade of tumour (Nutt et al, 1998). Matrix metalloproteinase 2 and
MMP9 activity was significantly enhanced in urine from patients
with highly invasive tumours (Sier et al, 2000), and also found to
be associated with high stage and grade of bladder tumours
(Gerhards et al, 2001). Patients with muscle invasive tumours were
found to have higher urinary concentrations of TIMP1 than those
with superficial tumours (Durkan et al, 2001).
Since EGFR in bladder cancer is associated with high stage and
grade of tumour, and urinary concentrations of EGF are high, this
study has investigated the effect of gefitinib on EGF-stimulated
growth in two human bladder tumour cell lines, and the effect on
MMP2, TIMP1 and TIMP2 levels found in the conditioned medium
from the cultured cells. Owing to its previous reported effect on
cell growth, the specific effect of TIMP1 on the growth of bladder
cell lines was also investigated.
MATERIALS AND METHODS
Cell culture
Two human bladder tumour cell lines, RT4 and RT112, were
routinely grown in the RPMI medium containing 10% foetal
bovine serum (FBS). These cell lines differ in their EGFR numbers,
with RT4 and RT112 cells containing 1.910
4 and 910
3
receptors per cell, respectively, as measured by FACS analysis
(Brotherick et al, 1994). All cells were negative for mycoplasma.
Growth of cells was measured using the sulphorhodamine B (SRB)
assay (Skehan et al, 1990). Cells were seeded in 96-well plates at
410
3 or 110
4 cells per well and incubated for 24h. The
medium was removed and the cells washed with phosphate-
buffered saline (PBS) and fresh medium either with or without
FBS was added for a further 24h. In a subset of experiments,
serum-free medium was used to remove exogenous growth
factors from cells to be treated with EGF. The medium was then
replaced with the test medium containing EGF (human recombi-
nant, Sigma-Aldrich, Poole, UK) at 10 or 50ngml
1 or gefitinib
(from 0.1–10mM) alone or in combination with EGF for the
required time. The cells were fixed with 25ml 50% trichloro-
acetic acid, stained with SRB and the plates were scanned for
absorbance at 570nm.
For the conditioned medium used in zymograms and Western
blotting, cell culture was as previously described using 145cm
2
tissue culture dishes and cells in the serum-free medium contain-
ing 0.1% bovine serum albumin (Nutt et al, 1998). The test
medium contained EGF (10, 50 or 100ngml
1) or gefitinib (1 or
5mM) or a combination, and cells were incubated for a further 48h.
The medium was removed, centrifuged to remove any cells and
stored at 201C prior to 10-fold concentration using Centricon-10
concentrators (Millipore (UK) Ltd, UK).
Cell lysates were used in Western blotting analysis to verify the
relative levels of EGFR. Phosphorylation of EGFR of cells grown in
the serum-free and serum-rich medium at basal levels and
following 10min stimulation with 10ngml
1 EGF were also
determined by Western blotting, using the Phospho-EGF Receptor
(Tyr992) polyclonal antibody (Cell Signalling Technology, USA).
The effect of TIMP1 on cell growth in both RT112 and RT4 cell
lines was studied using the SRB assay as above. A stock solution of
human TIMP1 (Chemicon International Ltd) was prepared in PBS
at 10mgml
1 and added to cells in the serum-free medium for up
to 4 days, in a range of final concentrations of 1–500ngml
1. Cells
were observed daily with the microscope before fixation.
Zymography
Zymography was performed using 10% polyacrylamide gels with
gelatin incorporated as a substrate for proteases (Zymogram Ready
Gels, Biorad, UK). Samples were mixed with a 5 sample buffer
(Herron et al, 1986) adapted as follows: 20ml sample buffer was
prepared using 12.5ml 0.5 M Tris-HCl buffer pH 6.8, 2.5g SDS, 1g
sucrose and 0.02g bromophenol blue. Stocks were stored frozen
and aliquots thawed as required. A 15ml total sample, generally
12ml sample with 3ml sample buffer, was loaded onto the gel.
Electrophoresis was performed at room temperature in Tris/
glycine/SDS buffer for 1.5h at 100V and the gels were renatured in
2.5% Triton X-100 for 30min at room temperature to remove SDS
from the gels and reactivate any MMPs present. The gels were
incubated overnight at 371C in a shaking water bath in
development buffer (50mM Tris-HCl pH 7.5, 200mM NaCl, 5mM
CaCl2, 0.02% Brij-35). They were then stained in 0.5% Coomassie
Blue R-250 in 40% methanol, 10% acetic acid for 1.5h and
destained in 40% methanol, 10% acetic acid for 1.5h with a rinse
and two changes of destain solution to visualise digested bands in
the gelatin matrix. The gels were photographed using a digital
camera and quantification was performed using Molecular
Dynamics ImageQuant software.
Western blot analysis
Western blotting was performed to investigate the presence of
TIMP1 and TIMP2 in the conditioned media. Following SDS–
PAGE electrophoresis and electroblotting (Towbin et al, 1979),
membranes were blocked using a 5% milk solution prior to
incubation with specific antibodies. Antibodies were obtained
from Oncogene Research Products and were used at a concentra-
tion of 1mgml
1. Tissue inhibitor of metalloproteinase 1 (Ab1)
and TIMP2 (Ab1) and a secondary HRP-conjugated antibody
(Goat-antimouse, Dako, Ely, UK) were used and detection was
performed using enhanced chemiluminescence (Amersham Bios-
ciences, UK).
RESULTS
EGF receptors in cell lines
The results of Western blotting analysis of the RT4 and RT112 cells
to confirm the relative levels of EGFR are shown in Figure 1(A).
More receptors are present in the RT4 cells, confirming previous
results of FACS analysis.
No phosphorylated EGF receptors were detectable in cells grown
in either the serum-free or serum-rich medium without additional
stimulus. Phosphorylated EGFR was apparent following 10min
stimulation with EGF in both the media. Results in Figure 1(B)
show the use of phospho-EGF receptor (Tyr992) antibody in
RT112 cells. Similar results were obtained with Tyr845, 1045 and
1068 antibodies.
Effect of gefitinib on cell growth
Human bladder cancer cell lines RT112 and RT4 were exposed to
continuous treatment with gefitinib at concentrations 0.1–10mMin
both the serum-rich (10%) and serum-free medium. The results
are shown in Figure 2. In the serum-rich medium, gefitinib from
0.1–5mM had no effect on the cell growth of RT112 cells over 4
days, whereas 10mM gefitinib reduced the growth by 50%
(Figure 2A). In contrast, the RT4 cells grown in the serum-rich
medium were more sensitive to gefitinib, with 5mM giving 50%
reduction in growth, and 10mM not only inhibiting cell growth but
Gefitinib inhibits bladder tumour cell growth
JE Nutt et al
1680
British Journal of Cancer (2004) 90(8), 1679–1685 & 2004 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
salso showing evidence of a reduction in cell number compared
with initial cell seeding levels (Figure 2C). Similar results were
obtained for RT4 cells grown in the serum-free medium
(Figure 2D). However, in the serum-free medium, RT112 cells
were markedly more sensitive to gefitinib, with 5mM decreasing cell
growth by 50% and 10mM inhibiting cell growth (Figure 2B).
Effect of gefitinib on EGF-stimulated cell growth
The results of EGF growth stimulation in the serum-free medium
and the inhibition of EGF-stimulated cell growth with gefitinib are
shown in Figure 3. In the RT112 cell line, following treatment with
gefitinib and 10ngml
1 EGF for 4 days, EGF-stimulated growth
was not inhibited by 0.1mM gefitinib, but was inhibited at 1, 5 and
10mM gefitinib (Figure 3A). At these higher concentrations,
comparable growth curves were obtained with gefitinib alone or
in the presence of EGF. Similar results were obtained using
50ngml
1 EGF, with 1mM gefitinib inhibiting the EGF stimulatory
effect (data not shown).
The results from the RT4 cell line following treatment with
50ngml
1 EGF and 0.1–10mM gefitinib for 4 days are shown in
Figure 3B. Again, comparable results were seen with the two doses
of EGF (results not shown), and only 0.1mM gefitinib did not
inhibit the EGF-stimulated growth.
Effect of gefitinib and EGF on MMP secretion
The conditioned media from cells treated with 1 or 5mM gefitinib
alone or with 10ngml
1 EGF were used for zymogram analysis.
The result of a zymogram, representative of the conditioned media
from three separate cell culture experiments, is shown in Figure 4.
Actin
EGFR
RT112
RT4
MW marker
42
201
kDa
250
98
P EGFR
MW marker
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SF+EGF
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A
B
Figure 1 (A) Western blot analysis of cell lysates from RT112 and RT4
cells showing the relative levels of EGFR. Actin is shown to verify equal
loading. (B) Western blot analysis of cell lysates from RT112 cells grown in
the serum-free (SF) or serum-rich (FBS) medium without or with 10min
treatment 10ngml
1 EGF. Phosphorylated EGFR (P EGFR) was detected
with a Tyr992 antibody.
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Figure 2 Cell growth, measured by the SRB assay, of RT112 cells (A and
B) and RT4 cells (C and D) in the medium containing 10% FBS (A and C)
or in the serum-free medium (B and D) with increasing concentrations of
gefitinib. Error bars show 7s.d. of six replicates in one representative
experiment. ’ Control medium; m 0.1mM gefitinib; . 1mM gefitinib; K
5mM gefitinib; & 10mM gefitinib.
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Figure 3 Effect of EGF and gefitinib on cell growth of RT112 (A) and
RT4 (B) cells in the serum-free medium after 4 days in culture. Error bars
show 7s.d. of six replicates in one representative experiment. Filled bars
show results with gefitinib alone, plain bars in the presence of EGF, at the
concentrations indicated.
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sThe medium from HT1080 cells is used as a control to demonstrate
bands of MMP9 and MMP2 activity. Matrix metalloproteinase 2
was detectable in all the media from RT112 cells. The active MMP2
was decreased following continuous EGF treatment alone, but
there was no change from the control levels in cells treated with
gefitinib alone or in combination with EGF, demonstrating the
inhibition of EGF action on the secretion of MMP2 activity by
gefitinib. Both concentrations of gefitinib used gave similar results,
with no indication of dose dependency of gefitinib in the
concentrations used, although their effects on growth differed.
From densitometry of the zymograms, the total gelatinolytic
activity in treated cells as a percentage of the controls for RT112
cells is shown in Figure 5, confirming the maximum effect on EGF-
stimulated MMP2 synthesis occurring with 1mM gefitinib. In the
RT4 cell culture, there were very low levels of secreted MMP2 in
the conditioned media and there was no detectable effect of EGF
and/or gefitinib on secreted metalloproteinases (Figure 4). There
was no evidence, in either cell line, of any MMP9 being secreted
into the conditioned media following treatment with EGF or
gefitinib.
Western blotting analysis for TIMP1 and TIMP2
The results of Western blotting analysis for the detection of TIMP1
and TIMP2 in the conditioned media from RT112 cells treated with
EGF and gefitinib alone or in combination are shown in Figure 6.
Tissue inhibitor of metalloproteinase 1 levels were increased three-
fold above the control levels (measured by densitometry) with both
50 and 100ngml
1 EGF. This level of TIMP1 was decreased in a
dose-dependent manner when the cells were incubated with
gefitinib for 48h. This was particularly evident with 50ngml
1
of EGF. The reverse effect was observed for TIMP2, with 10% of the
control level of protein being produced with 50ngml
1 EGF. The
effect of EGF was abolished in the presence of both doses of
gefitinib used. Equal loading of samples was seen in the albumin
band.
In the conditioned medium from RT4 cells, no TIMP1 or TIMP2
was detectable in any medium by Western blotting (data not
shown).
Effect of TIMP1 on cell growth
The morphological appearance of both cell lines showed no
obvious change over the 4 days treatment with TIMP1 at any of the
concentrations used. There was no stimulation or inhibition of cell
growth over 4 days with any concentration of TIMP1 in either cell
line (data not shown).
DISCUSSION
Strategies targeting the EGFR may well have a therapeutic potential
in bladder cancer, since the receptor is frequently expressed at
HT1080
Control
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Figure 4 Zymogram of the serum-free conditioned medium from RT112 and RT4 cells treated with EGF and gefitinib for 48h. The conditioned medium
from HT1080 cells treated with phorbol ester is included as a control to show bands of MMP9 and MMP2 activity.
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Figure 5 Matrix metalloproteinase 2 activity in the serum-free
conditioned medium at 48h from RT112 cells as a percentage of the
48h control value measured by densitometry of zymograms. Columns are
the mean of three separate tissue culture experiments; error bars are 7s.e.
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shigh levels in this disease and patients with tumours expressing
high levels of EGFR tend to have a poor prognosis (Mellon et al,
1995). The tyrosine kinase inhibitor, gefitinib, is targeted against
EGFR and is being used in clinical trials with objective responses
of antitumour activity being noted in non-small-cell lung cancer,
squamous cell carcinoma of the head and neck and in hormone-
refractory prostate cancer (Baselga and Averbuch, 2000; de Bono
and Rowinsky, 2002). The present study has investigated the effect
of gefitinib on growth in two human bladder cancer cell lines and
the effect on MMPs and TIMPs, both involved in tumour
progression and metastasis and known to be modulated by EGF
receptor activity.
The two cell lines studied showed differing sensitivities to
gefitinib. In the serum-rich medium, RT4 cells were more sensitive
to gefitinib than RT112 cells. This was surprising since the RT4
cells contain approximately twice the number of EGF receptors as
RT112 and suggests that, in spite of the lower levels of EGF
receptors, the growth of RT112 cells is more dependent on their
activity. There are mixed reports on the correlation of growth
inhibition by gefitinib and the EGFR status of cells. In one study,
the sensitivity of a panel of human breast cancer and other
epithelial tumour cell lines to gefitinib was found not to be
dependent on overexpression of EGFR (Moasser et al, 2001), and
was also suggested to be related to erbB2 expression (Anderson
et al, 2001). However, an inverse correlation between IC50 and
EGFR levels in a range of tumour cell lines has been reported
(Magne et al, 2002). In another study, four different bladder
tumour cell lines have been reported to show a dose-dependent
inhibition of cell proliferation when treated with gefitinib, which
correlated with the EGFR protein level (Meye et al, 2001).
In contrast, in the present study, in the serum-free medium,
where there are no exogenous growth factors apart from those
produced by autocrine stimulation, similar sensitivities were
found, with 10mM gefitinib preventing cell growth. Gefitinib also
prevented the EGF-stimulated cell growth in both RT112 and RT4
cell lines in concentrations of 1mM and above. These results are
similar to a study of four EGFR-positive ovarian cancer cell lines
(Sewell et al, 2002) where growth stimulation with TGFa, another
ligand for EGFR, was completely inhibited by gefitinib concentra-
tions of 0.3mM and above.
Metalloproteinases are central to both matrix degradation and
remodelling, and their role in tumour invasion and metastasis is
now well established. The gelatinases, MMP2 and MMP9, are
particularly important in the degradation of the basement
membrane. Matrix metalloproteinase 2 is reported to be consti-
tutively expressed in a variety of cells (Benbow and Brinckerhoff,
1997), and in the present study it was found to be present in the
serum-free conditioned medium of untreated cells. The level of
total MMP2 (both latent and active) was, however, found to be
consistently reduced in the RT112 cell line when treated with EGF,
with a noticeable reduction particularly in the active form of the
enzyme. This was reversed to the control levels by gefitinib alone
or in the presence of EGF, consistent with the inhibition of the EGF
effect on downregulation of MMP2 by the action of gefitinib on the
EGFR. Matrix metalloproteinase 2 is activated by activated
membrane-bound metalloproteinase MT1-MMP (Sato et al,
1994), and TIMP2 is also involved in the ternary complex for
MMP2 activation, which releases active MMP2 from the cell
surface (Strongin et al, 1995). Tissue inhibitor of metalloproteinase
2 also inhibits MMP2 activity directly by forming a 1:1 complex.
The decrease in MMP2 in the conditioned medium was mirrored
by the decrease in TIMP2 with EGF, which was again reversed by
treatment with gefitinib. This effect of EGF is somewhat surprising
since most MMPs, apart from MMP2, which lacks an AP1-binding
site in its promoter region, are induced by cytokines and growth
factors (Benbow and Brinckerhoff, 1997). Further studies are
required to investigate whether the reduction in MMP2 protein is
due to inhibition by TIMP2, increased levels of MT1-MMP on the
cell surface or changes in the levels of mRNA, and hence in the
levels of transcription via an alternative signalling pathway other
than that involving the AP1 transcription site. Variants in the
MMP2 gene have recently been reported (Price et al, 2001), in
which an SP1-type promoter site is disrupted and displays a lower
promoter activity. A study of a breast cancer cell lines stimulated
with EGF showed an increase in MMP9 but not MMP2, but this
increase was not inhibited by the tyrosine kinase inhibitor
PD153035 (Kondapaka et al, 1997).
EGF and gefitinib produced opposite effects on TIMP1 and
TIMP2 in the conditioned medium of RT112 cells, again with
gefitinib reversing the EGF response. A previous study of urinary
TIMP1 concentrations (Durkan et al, 2001) showed higher
concentrations in muscle invasive compared with superficial
tumours, and a lower MMP1:TIMP1 ratio was found in invasive
tumours. A low urinary MMP9:TIMP1 ratio was also shown to
indicate an increased risk of tumour recurrence (Durkan et al,
2003). Tissue inhibitor of metalloproteinase 2 and MMP2 have also
been investigated in bladder cancer. Using RT–PCR, invasive
bladder tumour samples were found to have higher expression of
MMP2 and TIMP2 compared to superficial tumours, and high
levels of MMP2, TIMP2 and MT1-MMP were associated with
decreased patient survival (Kanayama et al, 1998). MT1-MMP has
been shown to be present in both invasive and superficial bladder
carcinoma cells (Kitagawa et al, 1998). Similar results were
reported using immunohistochemical studies of TIMP2 in invasive
tumours (Grignon et al, 1996). Serum MMP2:TIMP2 ratios have
also been studied, with higher ratios occurring in patients showing
recurrence or lower disease survival (Gohji et al, 1996).
RT112 cells have previously been shown to invade the
subepithelial capillary bed in a human bladder tumour invasion
model, whereas RT4 cells were noninvasive (Booth et al, 1997). An
increased TIMP1 secretion with EGF, seen in this study in RT112
cells (Figure 6), would initially suggest more MMP inhibition, and
hence less invasion. The increase in TIMP2 in the presence of
gefitinib, with or without EGF, would also indicate potentially less
invasion, and would suggest a possible antimetastatic effect of
gefitinib. The increase in TIMP2 would also enhance the inhibition
TIMP1
TIMP2
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ZD1839 1 M
ZD1839 5 M
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EGF 100 ng ml −1
 
EGF 100 ng ml −1 +ZD1839 1M
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Figure 6 Western blot analysis for TIMP1 and TIMP2 in the conditioned
medium from RT112 cells following 48h treatment with EGF and/or
gefitinib. The albumin band seen with the TIMP1 antibody verifies equal
loading of samples.
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The role of TIMPs, however, has been suggested not to be purely
the inhibitory action on MMPs, but also that TIMPs have growth-
promoting activity. Tissue inhibitor of metalloproteinase 2 was
reported to have growth-promoting activity in a wide range of
human, bovine and murine cell lines at a concentration of
10ngml
1, 10-fold lower than that of TIMP1 (Hayakawa et al,
1994). However, no growth-promoting activity was found at
concentrations greater then 1mgml
1, when matrix degradation
is inhibited (De Clerck et al, 1994). In the RT112 and RT4 bladder
cell lines studied here, no effect of TIMP1 on growth was detected,
using concentrations from 1 to 500ngml
1. A recent study has
shown stimulation of melanoma cell lines by TIMPs, and that
during melanoma progression growth responses to TIMP1 and
TIMP2 may gradually change (Hoashi et al, 2001).
The role of TIMPs in bladder cancer and their regulation by EGF
receptor signalling pathways is obviously complex and requires
further investigation. The use of gefitinib may be beneficial in
bladder tumours, not only for its effect on EGFR tyrosine kinase-
dependent growth but also the EGF receptor-mediated effect on
TIMPs.
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